Lactate - CAS:50-21-5 - KKL Med Inc.

您当前的位置：

Lactate (Synonyms:乳酸)

目录号 : KM31160 CAS No. : 50-21-5 纯度 : 85%

Data Sheet SDS 产品使用指南

Lactate (Lactate acid) is the product of glycolysis. Lactate is produced by oxygen lack in contracting skeletal muscle in vivo, and can be removed under fully aerobic conditions. Lactate can be as a hemodynamic marker in the critically ill.

规格	价格	是否有货	数量
100mg		In-stock	立即试用
500mg		In-stock
1g	询价	In-stock
5g	询价	In-stock

加入购物车大包装询价

Other Forms of Rapamycin:

Neuraminidase, Microorganism In-stock
Human IgG4, kappa Recombinant Isotype Control Antibody (HyHEL-10) In-stock
Anti-IL11 Antibody (X203) In-stock
BI-765423 In-stock
DSPE-PEG2000-VHPKQHRGGSKGC In-stock

KKL Med 的所有产品和服务仅用于科学研究，不能被用于人体，兽医，我们也不向个人提供产品和服务。

生物活性

体外研究

Lactic acid (20 mM; 24, 48 hours) significantly reduced cell proliferation and migration, and converted cell metabolism to oxidative phosphorylation.
Lactic acid (20 mM; 24 hours) significantly increased the protein and mRNA expression levels of MCT1 and HCAR1 .

Cell Proliferation Assay

Cell Line:	Uveal melanoma 92.1 cells
Concentration:	20 mM
Incubation Time:	24, 48 hours
Result:	Inhibited cell proliferation and migration.

Western Blot Analysis

Cell Line:	Uveal melanoma cells
Concentration:	20 mM
Incubation Time:	24 hours
Result:	Showed an increase in the protein expression levels of MCT1 and HCAR1

体内研究

Lactic acid (1.6 g/kg; pH 7.4; injection in white); Once a day; From day 8 to day 30, CD8+T cell-dependent tumor growth inhibition was observed in the MC38 colon cancer model.
Note: Before administering drugs to animals, the pH of the working solution needs to be adjusted to around 7.4.

Animal Model:	Female C57BL/6 mice with MC38 colon cancer cells
Dosage:	1.6 g/kg
Administration:	Subcutaneous; daily from Day 8 to 30 days
Result:	Significantly suppressed tumor growth.

分子式

C₃H₆O₃

分子量

90.08

CAS号

50-21-5

中文名称

乳酸

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

2-8°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

溶解性数据

In Vitro:

DMSO : ≥ 200 mg/mL (2220.25 mM)

H2O : ≥ 200 mg/mL (2220.25 mM)

* "≥" means soluble, but saturation unknown

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	11.1012 mL	55.5062 mL	111.0124 mL
5 mM	2.2202 mL	11.1012 mL	22.2025 mL
10 mM	1.1101 mL	5.5506 mL	11.1012 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO → 40% PEG300 → 5% Tween-80 → 45% saline

Solubility: ≥ 5 mg/mL (55.51 mM); Clear solution

此方案可获得 ≥ 5 mg/mL (55.51 mM，饱和度未知) 的澄清溶液。

以 1 mL 工作液为例，取 100 μL 50.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
2.

请依序添加每种溶剂： 10% DMSO → 90% (20% SBE-β-CD in saline)

Solubility: ≥ 5 mg/mL (55.51 mM); Clear solution

此方案可获得 ≥ 5 mg/mL (55.51 mM，饱和度未知) 的澄清溶液。

以 1 mL 工作液为例，取 100 μL 50.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
3.

请依序添加每种溶剂： 10% DMSO → 90% corn oil

Solubility: ≥ 5 mg/mL (55.51 mM); Clear solution

此方案可获得 ≥ 5 mg/mL (55.51 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

以 1 mL 工作液为例，取 100 μL 50.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。